New Horizons Study 2019 – 2023

Overview

Prior to the inception of the New Horizons Collaborative, no multi-country data were collected regarding the demographic or clinical characteristics of the target patient population (i.e., children, adolescents, and young people < 25 years in need of second- or third-line HIV/AIDS treatment). Therefore, the current activity proposes to collect cross-sectional demographic and clinical data at baseline and every six months for patients receiving DRV and/or ETR across participating New Horizons countries. This activity will comprise data abstraction of a key demographic, clinical, laboratory and case history indicators and outcomes on each patient who ever received DRV and/or ETR.

The objectives of this data collection activity are to:

• Describe the baseline demographics, clinical and laboratory profile of patients who ever received DRV and/or ETR, at the time of initiation on DRV and/or ETR;
• Describe the clinical and laboratory profile of patients who ever received DRV and/or ETR every 6 months from the first data collection point through 2021;
• Describe dynamics in HIV drug resistance mutations among patients who fail treatment on new regimens including DRV and/or ETR;
• Describe demographics, clinical and laboratory profile of young adults who transition out of the donation program after the age of 25 years at 12 months after their transition